Looking to publish in Human Vaccines & Immunotherapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginHuman Vaccines & Immunotherapeutics is an international open access peer-reviewed journal focused on human vaccinology and immunotherapy. It publishes research on novel vaccines and immunotherapeutics, preclinical studies, clinical trials, disease mechanisms, licensed products, vaccine acceptance and hesitancy, policy, safety, surveillance, epidemiology, pharmaco-economics, and related public health topics. The journal operates single-anonymized peer review, is affiliated with the International Society for Vaccines and the Association for Cancer Immunotherapy, and has been fully open access since Volume 18 in 2022.
Looking to publish in Human Vaccines & Immunotherapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Human Vaccines & Immunotherapeutics accepts the following article types. Click on an article type to view submission instructions.
Research Articles
Review Article
State-Of-The-Art Reviews
Case Report
Rapid Communication
Mini-Reviews
Recent Publications
Multifocal mucocutaneous herpes simplex virus type 1 infection temporally associated with seasonal influenza vaccination in a young adult without a known immunocompromising condition: A case report
Yen-Hung Liu, Pei-Lun Hung
Healthcare resource use and costs following RSV-related hospitalizations among US adults aged 50 years and older
David Singer, Yan Wang, Elizabeth M. La, Aozhou Wu, Susan I. Gerber, Keith A. Betts
Measles as tracer and tugboat: Why eradication can strengthen immunization systems
David N. Durrheim, Jon K. Andrus, Mimi Mynak, David Githanga, Mira Kojouharova, Nadia Teleb
From vaccine availability to effective deployment: Closing the arboviral vaccine access gap
Kok Keng Tee, Dongkui Mu, Binghui Wang, Xueshan Xia
More than a moment: Evolving decisions among eligible volunteers in phase 1 COVID-19 vaccine trials
Donna M. Halperin, Bailey M. Selig, Brian R. J. Condran, Alexa J. Davis, Carrie A. Whittle, Joanne M. Langley, Scott A. Halperin
Frequently asked questions
How long does it take to publish?
25 days average from submission to first decision; 48 days average from submission to first post-review decision; 14 days average from acceptance to online publication.
Reformat to Human Vaccines & Immunotherapeutics using Livewrite PremiumIs a cover letter required?
A cover letter is not used for APC waiver requests. Waiver requests must be made at the time of online submission, not in a cover letter.
Reformat to Human Vaccines & Immunotherapeutics using Livewrite PremiumWhat are the publication costs?
Open access costs may be covered by a Taylor & Francis open access agreement; journal-specific charges vary.
Reformat to Human Vaccines & Immunotherapeutics using Livewrite Premium